Loading…
IDEAYA Biosciences, Inc., a precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company offers Darovasertib, an oral, potent, and selective protein kinase C (PKC) inhibitor for the treatment of uveal melanoma, ocular cancer driven by GNAQ/11 mutations, and is being evaluated in multiple clinical trials as monotherapy and in combination with crizotinib for metastatic, neoadjuvant, and adjuvant settings. The company also offers IDE849, a DLL3 antibody drug conjugate inhibitor that is in a Phase 1 clinical trial for the treatment of SCLC and neuroendocrine carcinomas; IDE034, a B7H3/PTK7 topo-I-payload bispecific BsADC; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 dose optimization trial; IDE705 (GSK101), a Poly Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other mutations associated with HRD; IDE397, a MAT2A inhibitor for MTAP-deleted tumors; IDE892, a PRMT5 inhibitor; IDE574 selectively inhibits KAT6/7 and is in Phase 1 dose escalation trial for patients with breast, lung, prostate, and colorectal cancers; IDE275 oral small molecule inhibitor of the helicase domain of the Werner protein (WRN) and is in a Phase 1 clinical trial. In addition, the company offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform. The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Gilead Sciences, Inc., Novartis, Biocytogen, Cancer Research UK, the University of Manchester, Jiangsu Hengrui Pharmaceuticals Co., Ltd., and Les Laboratoires Servie. It also has a clinical collaboration agreement with AstraZeneca plc to evaluate the efficacy and safety of IDE849, an antibody-drug conjugate. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $219M | $-155M | $-114M | $-73M | -11.1% | 3024.4% | - |
| 2024 | $7M | $-323M | $-274M | $-251M | -25.9% | -70.1% | - |
| 2023 | $23M | $-130M | $-113M | $-118M | -18.2% | -54.1% | - |
| 2022 | $51M | $-59M | $-59M | $-91M | -16.8% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total Revenue | 50.93 | 23.39 | 7 | 218.71 |
| Operating Expense | 113.43 | 157.81 | 333.98 | 378.02 |
| Operating Income | -62.50 | -134.43 | -326.98 | -159.31 |
| EBITDA | -58.99 | -130.42 | -323.14 | -154.72 |
| EBIT | -62.50 | -134.43 | -326.98 | -159.31 |
| Pretax Income | -58.66 | -112.96 | -274.48 | -113.70 |
| Net Income | -58.66 | -112.96 | -274.48 | -113.70 |
| Net Income Common Stockholders | -58.66 | -112.96 | -274.48 | -113.70 |
| Total Expenses | 113.43 | 157.81 | 333.98 | 378.02 |
| Interest Income | 3.85 | 21.47 | 52.50 | 45.62 |
| Research And Development | 89.54 | 129.51 | 294.67 | 314.70 |
| Selling General And Administration | 23.90 | 28.31 | 39.30 | 63.32 |
| Normalized EBITDA | -58.99 | -130.42 | -323.14 | -154.72 |
| Normalized Income | -58.66 | -112.96 | -274.48 | -113.70 |
| Basic EPS | -1.42 | -1.96 | -3.36 | 0 |
| Diluted EPS | -1.42 | -1.96 | -3.36 | 0 |
| Tax Effect Of Unusual Items | 0 | 0 | 0 | 0 |
| Tax Rate For Calcs | 0 | 0 | 0 | 0 |
| Net Income From Continuing Operation Net Minority Interest | -58.66 | -112.96 | -274.48 | -113.70 |
| Reconciled Depreciation | 3.52 | 4.01 | 3.83 | 4.59 |
| Net Interest Income | 3.85 | 21.47 | 52.50 | 45.62 |
| Net Income From Continuing And Discontinued Operation | -58.66 | -112.96 | -274.48 | -113.70 |
| Total Operating Income As Reported | -62.50 | -134.43 | -326.98 | -159.31 |
| Diluted Average Shares | 41.44 | 57.52 | 81.68 | 0 |
| Basic Average Shares | 41.44 | 57.52 | 81.68 | 0 |
| Diluted NI Availto Com Stockholders | -58.66 | -112.96 | -274.48 | -113.70 |
| Otherunder Preferred Stock Dividend | 2.16 | 0 | 0 | 0 |
| Net Income Including Noncontrolling Interests | -58.66 | -112.96 | -274.48 | -113.70 |
| Net Income Continuous Operations | -58.66 | -112.96 | -274.48 | -113.70 |
| Net Non Operating Interest Income Expense | 3.85 | 21.47 | 52.50 | 45.62 |
| Interest Income Non Operating | 3.85 | 21.47 | 52.50 | 45.62 |
| General And Administrative Expense | 23.90 | 28.31 | 39.30 | 63.32 |
| Other Gand A | 23.90 | 28.31 | 39.30 | 63.32 |
| Operating Revenue | 50.93 | 23.39 | 7 | 218.71 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| IDEAYA Biosciences, Inc.this co. | IDYA | $2.5B | - | 2.41 | -11.1% | -11.82 |
| Immunome, Inc. | IMNM | $2.6B | - | 4.09 | -33.5% | -9.20 |
| Enliven Therapeutics, Inc. | ELVN | $2.6B | - | 5.48 | -22.6% | -17.36 |
| Vera Therapeutics, Inc. | VERA | $2.6B | - | 4.23 | -49.6% | -6.09 |
| Heartflow, Inc. | HTFL | $2.5B | - |
| 8.38 |
| -38.8% |
| -37.97 |
| Celldex Therapeutics, Inc. | CLDX | $2.5B | - | 4.06 | -49.1% | -5.72 |
| Disc Medicine, Inc. | IRON | $2.5B | - | 3.38 | -28.7% | -7.48 |
| Guardian Pharmacy Services, Inc. | GRDN | $2.4B | 48.17 | 11.56 | 22.6% | 23.10 |
| Relay Therapeutics, Inc. | RLAY | $2.4B | - | 3.85 | -48.8% | -5.76 |
| Peer Median | - | 48.17 | 4.16 | -36.2% | -6.79 | |